BOULDER, Colo. & BEVERLY, Mass. -- (BUSINESS WIRE) -- Enzymatics today launches a new targeted sequencing assay for detecting and identifying fusions of 26 genes associated with sarcoma. Using Enzymatics’ proprietary Anchored Multiplex PCR™-based enrichment, fusions of all genes in the panel can be identified in a single sequencing run, without prior knowledge of fusion partners or breakpoints. The assay will join the ALK, RET, ROS1 v2 panel and the Heme panel as the newest addition to the Archer™ FusionPlex™ product line.
About Archer™ FusionPlex™ Assays
Archer™ FusionPlex™ assays are target-enrichment assays used to create libraries for next-generation sequencing from as little as 20ng input nucleic acid. In conjunction with Archer™ Universal RNA Fusion Detection Kits and Archer™ MBC Adapters, these assays simultaneously detect and identify fusions of targeted genes. The FusionPlex™ assays are FFPE compatible and run on both Illumina® and Ion Torrent™ next-generation sequencing platforms.
Once sequenced, Archer™ FusionPlex™ libraries can be analyzed via the Archer™ Analysis Pipeline, a proprietary informatics analysis package that quickly detects and identifies fusion partners of assay genes as well as selected indels and point mutations.
Note: Archer™ kits and analysis software are for research use only and not for use in diagnostic procedures.
Enzymatics is a leading producer of sample preparation reagents, assays, kits and software for life science research and applied science customers worldwide. We are experts in the fields of DNA sequencing and PCR, and our business units include:
Our passion for quality, responsiveness and flexibility is catalyzing the genomic healthcare revolution. www.enzymatics.com